

June 10, 2025  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## Revision to Earnings Forecast for FY 2025

TOKYO, Japan, June 10, 2025 – Symbio Pharmaceuticals Limited (Headquarters: Tokyo, “Symbio” or the “Company”) today announced that the Company’s Board of Directors today approved the following revision to the earnings forecast for the fiscal year ending December 31, 2025. The earnings forecast was previously announced on February 6, 2025. The revision reflects the Company’s current performance trends and outlook.

### 1. Revision to Earnings Forecast

#### (i) Revision to Earnings Forecast for fiscal year 2025 (January 1, 2025 to December 31, 2025)

	Net Sales	Operating Profit	Ordinary Profit	Profit attributable to owners of parent	Earnings per share
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
Previous Forecast (A)	1,858	(4,263)	(4,347)	(4,468)	(80.45)
Revised Forecast (B)	1,400	(4,262)	(4,467)	(4,592)	(95.95)
Difference (B-A)	(458)	1	(120)	(124)	—
Percentage Change (%)	(24.7)	0.0	(2.8)	(2.8)	—
[Reference] Prior Year Results (FY 2024)	2,452	(3,876)	(3,689)	(3,833)	(85.00)

#### (ii) Reasons for revision

The ongoing shift to generic drugs at medical institutions, and the decline in prescription opportunities due to the expansion of treatment options, continue to impact sales of TREAKISYM®. For these reasons, the Company has does not expect sales to recover in the second half of the fiscal year. As a result, the Company projects Net Sales for the fiscal year ending December 31, 2025 to reach 1,400 million yen, reflecting a decrease of 458 million yen (or 24.7%) compared to the prior forecast.

Efforts to reduce expenses other than development costs have resulted in an expected overall decrease in sales and

general administrative expenses to 5,330 million yen (a decrease of 290 million yen compared to the prior forecast). Preparations toward the start of the global phase 3 clinical trial for adenovirus infection after hematopoietic stem cell transplantation (“HSCT”), the ongoing global phase 1b clinical trial for NK/T-cell lymphoma, and the ongoing phase 2 clinical trial for CMV infection after HSCT are progressing as planned.

The Company expects an operating loss of 4,262 million yen (a decrease in loss of 1 million yen compared to the prior forecast). Due to losses on dollar-denominated deposits arising from exchange rate fluctuations on foreign currency-denominated assets, and increased expenses related to bond issuance, the ordinary loss is expected to be 4,467 million yen (an additional loss of 120 million yen compared to the prior forecast). The loss attributable to the owners of parent is expected to be 4,592 million yen (an additional loss of 124 million yen compared to the prior forecast).

The assumed exchange rate has been revised to 1 US dollar = 142.00 yen (compared to 1 US dollar = 150.00 yen for the prior forecast).

Earnings forecasts, financial projections, and other forecasts or forward-looking statements contained in this disclosure have been prepared by the Company at its discretion and based on information available to the Company as of the date of this disclosure. Actual results may vary materially from the information contained in this disclosure as a result of changes to or in business, economic, financial, or other assumptions and conditions.

**[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125